• In our study we provide evidence

  2024-08-20

  

  In our study we provide evidence for the existence of an endosome-lysosomal pathway for the proteolytic degradation of AR triggered by its interaction with the ESCRT-I component TSG101. The following findings of this study support this notion: (1) We showed that TS101 interacts with endogenous or ec

• br AMPK as a druggable target

  2024-08-20

  

  AMPK as a druggable target AMPK signaling has attracted considerable attention within the past decades, owing to the capacity of pharmacological compounds (e.g., 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside [AICAR] and metformin) or natural compounds (e.g., resveratrol) to activate AMPK in

• In hypothalamus as indicated in Fig column A and

  2024-08-20

  

  In hypothalamus, as indicated in Fig. 2 (column A) and following the enzymatic cascade represented in Fig. 1, we could hypothesize a predominance of Ang 2–10 and Ang III formation in SHR compared to WKY. This is in agreement with previous results that reported significant higher rate of Ang 2–10 for

• br Results br Discussion By using

  2024-08-20

  

  Results Discussion By using an unbiased proteomic screen for xCT binding partners, followed by functional validation, we have made the surprising discovery that mTORC2 regulates amino Cyt 387 metabolism in tumor cells by phosphorylating serine 26 of the cystine-glutamate antiporter xCT on its

• br Acknowledgements This work was supported by a

  2024-08-20

  

  Acknowledgements This work was supported by a grant from the National Science Foundation (IOS- 1353366), the Hatch Program of the National Institute of Food and Agriculture (VA-135908) and the Virginia Agricultural Experiment Station, to G.P. Introduction With steadily rising number of affect

• A limitation of the NIA

  2024-08-20

  

  A limitation of the 2011 NIA-AA recommendations was that biomarkers were grouped into just two categories—amyloid and tau-related neurodegeneration. Tauopathy and neurodegeneration were placed into the same biomarker category. In persons with only AD, it is reasonable to assume that neurodegeneratio

• There are several strengths and weaknesses of the current

  2024-08-20

  

  There are several strengths and weaknesses of the current investigation which merit consideration. Obviously, the current findings are important and less prone to bias than findings from traditional observational epidemiological studies, because causal investigations with the use of genetic variants

• ALK fusion positive NSCLC is clinically actionable

  2024-08-20

  

  ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective

• All desired compounds with a carboxylic acid substituent at

  2024-08-20

  

  All desired compounds with a carboxylic AZ 10606120 dihydrochloride substituent at N1 position of the quinoxalinone scaffold and a variety of aromatic substituents at C3 position were obtained by the syntheses starting from methoxy-substituted 3-chloro-quinoxalin-2(1)-ones () prepared as previously

• Introduction hydroxytryptamine HT is found throughout the bo

  2024-08-20

  

  Introduction 5-hydroxytryptamine (5-HT) is found throughout the body and influences smooth muscle activity in various tissues including the intestine, vasculature and urinary Probucol (Kim and Camilleri, 2000, Klarskov and Horby-Petersen, 1986, Mohammad-Zadeh et al., 2008). The current classificati

• Pituitary adenylate cyclase activating polypeptide PACAP is

  2024-08-20

  

  Pituitary adenylate cyclase-activating polypeptide (PACAP) is a member of the secretin/growth hormone-releasing hormone (GHRH)/vasoactive intestinal peptide (VIP) family, with potent anti-inflammatory and potent cytoprotective properties [[6], [7], [8], [9], [10], [11], [12], [13]]. PACAP exists as

• Our results using RT PCR confirm earlier findings Wilisch et

  2024-08-19

  

  Our results using RT-PCR confirm earlier findings (Wilisch et al., 1999, Bruno et al., 2004) including the presence of both the P3A+ and P3A− isoforms of the α-subunit (Beeson et al., 1990). The lack of detection of the ε-subunit mRNAs in some thymomas, and lack of α-, β-, δ- and γ-subunit mRNAs by

• The cytoplasmic domain of muscle AChR is not

  2024-08-19

  

  The cytoplasmic domain of muscle AChR is not accessible to nucleoside transporters in vivo. Theoretically, therapy with the cytoplasmic domains should be safe. Safety is demonstrated by the facts that: (1) rats repeatedly immunized with the cytoplasmic domains in TiterMax adjuvant do not develop EAM

• The purpose of the present study

  2024-08-19

  

  The purpose of the present study is (1) to characterize AChE from the monogonont B. koreanus and to analyze the modulation of the AChE activity and its transcription level after exposure to six pharmaceuticals, (2) to evaluate the usefulness of AChE as a molecular biomarker upon pharmaceutical expos

• br COX and LOX in post mortem AD

  2024-08-19

  

  COX and 5-LOX in post-mortem AD brain Minghetti (2004) reviewed the findings on COX-2 mRNA levels in AD brains, pointing out that the available evidence demonstrated either decreased or increased levels, possibly because of the short half-life of COX-2 transcripts or individual variability. Histo

15199 records 51/1014 page Previous Next First page 上5页 5152535455 下5页 Last page